WO2002016943A3 - Differential immunoassay - Google Patents

Differential immunoassay Download PDF

Info

Publication number
WO2002016943A3
WO2002016943A3 PCT/IB2001/001531 IB0101531W WO0216943A3 WO 2002016943 A3 WO2002016943 A3 WO 2002016943A3 IB 0101531 W IB0101531 W IB 0101531W WO 0216943 A3 WO0216943 A3 WO 0216943A3
Authority
WO
WIPO (PCT)
Prior art keywords
analyte
source
level
sample
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2001/001531
Other languages
French (fr)
Other versions
WO2002016943A2 (en
Inventor
Qinwei Shi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spectral Diagnostics Inc Canada
Original Assignee
Spectral Diagnostics Inc Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectral Diagnostics Inc Canada filed Critical Spectral Diagnostics Inc Canada
Priority to CA002420327A priority Critical patent/CA2420327A1/en
Priority to DE60129855T priority patent/DE60129855D1/en
Priority to EP01963291A priority patent/EP1386164B1/en
Priority to AU2001284317A priority patent/AU2001284317A1/en
Publication of WO2002016943A2 publication Critical patent/WO2002016943A2/en
Anticipated expiration legal-status Critical
Publication of WO2002016943A3 publication Critical patent/WO2002016943A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/972—Modified antibody, e.g. hybrid, bifunctional
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/819—Multifunctional antigen or antibody

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides assay methods and kits that in general measure the level of a first analyte in a sample reduced by the level of a second analyte present in the same sample. In one embodiment, where levels of a first analyte from a first source is desirably determined and first analyte in the sample released from a second source is accompanied by proportional co-release of a second analyte, the assay identifies the level of first analyte released only from the first source. For analytes within bodily fluids, the assay can differentiate between elevated levels of analyte specific to the particular physiological or pathological state and elevated levels not specific to the particular state, providing single tests with diagnostic utility.
PCT/IB2001/001531 2000-08-24 2001-08-24 Differential immunoassay Ceased WO2002016943A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002420327A CA2420327A1 (en) 2000-08-24 2001-08-24 Differential immunoassay
DE60129855T DE60129855D1 (en) 2000-08-24 2001-08-24 DIFFERENTIAL IMMUNOASSAY FOR MYOGLOBIN
EP01963291A EP1386164B1 (en) 2000-08-24 2001-08-24 Differential immunoassay for myoglobin
AU2001284317A AU2001284317A1 (en) 2000-08-24 2001-08-24 Differential immunoassay

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22753600P 2000-08-24 2000-08-24
US60/227,536 2000-08-24
US29249701P 2001-05-21 2001-05-21
US60/292,497 2001-05-21
US09/938,270 US6673562B2 (en) 2000-08-24 2001-08-23 Differential immunoassay

Publications (2)

Publication Number Publication Date
WO2002016943A2 WO2002016943A2 (en) 2002-02-28
WO2002016943A3 true WO2002016943A3 (en) 2003-10-23

Family

ID=27397733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/001531 Ceased WO2002016943A2 (en) 2000-08-24 2001-08-24 Differential immunoassay

Country Status (5)

Country Link
US (3) US6673562B2 (en)
EP (1) EP1386164B1 (en)
AT (1) ATE369564T1 (en)
DE (1) DE60129855D1 (en)
WO (1) WO2002016943A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233107D1 (en) * 2002-01-09 2009-09-10 Inverness Medical Switzerland Test strips containing control agents and timing agents
JP2007518062A (en) * 2003-09-29 2007-07-05 バイオサイト インコーポレイテッド Method for diagnosing sepsis and composition for diagnosing
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
WO2006031216A1 (en) * 2004-09-10 2006-03-23 Metrika, Inc. Quantitative immunoassays using tag/anti-tag chemistry
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
CA2624569A1 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
CN100367034C (en) * 2005-10-20 2008-02-06 上海交通大学 Measurement method of fluorescence quenching of immune colloidal gold particles
WO2008030546A2 (en) * 2006-09-06 2008-03-13 Ouantrx Biomedical Corporation Lateral flow test strip with migrating label
EP1956096A1 (en) * 2007-02-12 2008-08-13 Université Catholique de Louvain Method, device and kit for determining conditions related to a dysfunction of the renal proximal tubule
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
WO2009027514A1 (en) * 2007-08-30 2009-03-05 Roche Diagnostics Gmbh Means and methods for the discrimination of gdf-15 elevation related or unrelated to cardiac disorders
WO2010129265A2 (en) * 2009-04-27 2010-11-11 The Research Foundation Of State University Of New York Compositions comprising monomeric streptavidin and methods for using same
DK3684949T3 (en) 2017-09-22 2024-07-08 Univ Washington In situ combinatorial labeling of cellular molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1167919A (en) * 1996-06-11 1997-12-17 财团法人工业技术研究院 A kind of acute myocardial infarction detection reagent combination
WO2000008466A2 (en) * 1998-08-06 2000-02-17 Spectral Diagnostics, Inc. Analytical test device and method

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857453A (en) 1987-04-07 1989-08-15 Syntex (U.S.A.) Inc. Immunoassay device
US4900662A (en) 1987-07-21 1990-02-13 International Immunoassay Laboratories, Inc. CK-MM myocardial infarction immunoassay
US4952517A (en) 1988-02-08 1990-08-28 Hygeia Sciences, Inc. Positive step immunoassay
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
ES2088427T3 (en) 1989-03-21 1996-08-16 Hygeia Sciences Ltd SIMULTANEOUS TEST OF TWO ANALYTIES.
GB8916718D0 (en) 1989-07-21 1989-09-06 Vioclone Biolog Inc Use of creatine kinase and its isozyme ck-mb and human ventricular myosin light chain 1 in the diagnosis of heart failure
CA2027434C (en) 1990-10-12 1999-01-05 George Jackowski Diagnostic kit for diagnosing and distinguishing chest pain in early onset thereof
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
US5710008B1 (en) 1990-10-12 1999-09-07 Spectral Diagnostics Inc Method and device for diagnosing and distinguishing chest pain in early onset thereof
SE9101735D0 (en) 1991-06-07 1991-06-07 Pharmacia Biosensor Ab METHOD AND SENSOR MEANS FOR DETERMINING MYOCARDIAL INFARCTION MARKERS
DE19859912C2 (en) * 1998-12-23 2001-06-21 Aventis Res & Tech Gmbh & Co Test system for the detection of different markers, its production and use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1167919A (en) * 1996-06-11 1997-12-17 财团法人工业技术研究院 A kind of acute myocardial infarction detection reagent combination
WO2000008466A2 (en) * 1998-08-06 2000-02-17 Spectral Diagnostics, Inc. Analytical test device and method

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEUERLE JOHN R ET AL: "Characteristics of myoglobin, carbonic anhydrase III and the myoglobin/carbonic anhydrase III ratio in trauma, exercise, and myocardial infarction patients.", CLINICA CHIMICA ACTA, vol. 294, no. 1-2, April 2000 (2000-04-01), pages 115 - 128, XP002220436, ISSN: 0009-8981 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; December 1998 (1998-12-01), AZZAZY HASSAN M E ET AL: "Production and characterization of monoclonal antibodies to human carbonic anhydrase III.", XP002220437, Database accession no. PREV199900058935 *
DATABASE WPI Section Ch Week 200167, Derwent World Patents Index; Class B04, AN 2001-590388, XP002220438 *
HYBRIDOMA, vol. 17, no. 6, December 1998 (1998-12-01), pages 553 - 558, ISSN: 0272-457X *

Also Published As

Publication number Publication date
US20050260689A1 (en) 2005-11-24
EP1386164B1 (en) 2007-08-08
US6673562B2 (en) 2004-01-06
WO2002016943A2 (en) 2002-02-28
EP1386164A2 (en) 2004-02-04
US20020177241A1 (en) 2002-11-28
DE60129855D1 (en) 2007-09-20
ATE369564T1 (en) 2007-08-15
US20080311591A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
WO2003008933A3 (en) Test strip for a lateral flow assay
TWI256975B (en) Compositions containing a urea derivative dye for detecting an analyte and methods for using the same
ATE369564T1 (en) DIFFERENTIAL IMMUNOASSAY FOR MYOGLOBIN
AU2005225088B2 (en) Combination assay for alcohol and drugs of abuse
CA2435550A1 (en) System for monitoring the concentration of analytes in body fluids
ATE312349T1 (en) DIFFERENTIAL DIAGNOSIS OF NEURODEGENERATION
AU2002359891A1 (en) Test strip for determining concentration of triglycerides
MY134148A (en) Multi-layer reagent test strip
ATE354082T1 (en) ANALYZING DEVICE WITH REMOVABLE ELEMENT
WO2002027326A3 (en) Method and kit for the transderaml determination of analyte concentration in blood
MX2009006205A (en) Multiple analyte immunoassay.
WO2004000884A3 (en) Compositions and methods for apo-b48 and apo-b100 assay
WO2001073114A3 (en) Reagents and methods for detecting a reduced cofactor
WO2005112742A3 (en) Diagnostic test strip for collecting and detecting an analyte in a fluid sample and method for using same
DE60130919D1 (en) FLOW DEVICE, DIAGNOSTIC KIT CONTAINING THESE AND USE FOR THE DETECTION OF ANALYTES IN A SAMPLE
WO2003100006A3 (en) Method of improved prostate cancer detection
AU2002224794A1 (en) Method and test kit for detecting analytes in a sample
WO2005073405A3 (en) Catalytic polynucleotide and its use for determination of analytes
CA2361000A1 (en) Urinary trypsin inhibitor to diagnose aids
BR9913770A (en) Test procedure for determining cobalamin bound to transcobalamin ii (tcii) in a body sample, kit for use in a diagnostic assay, and use of holo-tc ii
EP1947459A3 (en) Differential immunoassay
EP1441224A3 (en) Enzyme inhibition immunoassay
MY106963A (en) Agglutination assay.
WO1998046993A3 (en) Method for diagnosing cancer by measuring the presence of creatine kinase inhibitor
AU2001280912B2 (en) Apparatus and method for determining the onset and presence of sepsis conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2420327

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001963291

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001963291

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001963291

Country of ref document: EP